2024
Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.
Lee K, Paek H, Huang L, Datta S, Annan A, Ofoegbu N, Higashi M, Hilton C, Rubinstein S, Cowan A, Kwok M, Warner J, Xu H, Wang X. Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models. Journal Of Clinical Oncology 2024, 42: 7568-7568. DOI: 10.1200/jco.2024.42.16_suppl.7568.Peer-Reviewed Original ResearchAmerican Society of Clinical Oncology conferencesConference abstractsOncology clinical trialsStudies due to variationsEfficacy outcomesP-valueTwo-proportion z-testClinical trialsMinimal residual disease negativityLung cancer studiesPublished articlesTrial abstractsGood partial responseCohort sizeCytokine release syndromeOutcome valuesFollow-up timeOverall response rateTrial findingsClinical trial findingsTime pointsCancer studiesClinical decisionsDiverse cancer typesComplete response
2023
PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model
Tien C, Draeger E, Guan F, Carlson D, Chen Z. PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model. Brachytherapy 2023, 22: s110. DOI: 10.1016/j.brachy.2023.06.184.Peer-Reviewed Original ResearchTumor control probabilityClinical trialsLinear-quadratic modelNumber of patientsPatient cohort sizeTCP curvesRadiobiological parametersVirtual clinical trialsGy-1Cohort sizeRange of dosesPatient outcomesReference cohortPatientsHeterogeneous cohortVirtual patientsNew trialsRadiobiological parameter valuesClonogenic populationPatient ordersControl probabilityGyInput model parametersTrialsCohortReproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational study.
Ostropolets A, Albogami Y, Conover M, Banda J, Baumgartner W, Blacketer C, Desai P, DuVall S, Fortin S, Gilbert J, Golozar A, Ide J, Kanter A, Kern D, Kim C, Lai L, Li C, Liu F, Lynch K, Minty E, Neves M, Ng D, Obene T, Pera V, Pratt N, Rao G, Rappoport N, Reinecke I, Saroufim P, Shoaibi A, Simon K, Suchard M, Swerdel J, Voss E, Weaver J, Zhang L, Hripcsak G, Ryan P. Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational study. Journal Of The American Medical Informatics Association 2023, 30: 859-868. PMID: 36826399, PMCID: PMC10114120, DOI: 10.1093/jamia/ocad009.Peer-Reviewed Original ResearchConceptsObservational studyCohort definitionsPatient characteristicsImpact patient careCohort sizeFree-text descriptionsPatient careTeam's interpretationClinical codingInclusion criteriaPatient overlapResearch teamMedian agreementInvestigate discordanceTeamCohortBaseline characteristicsQualified researchersAnalytical codePatientsCareImplementationStudyBaseline
2022
Analytical Approaches to Uncover Genetic Associations for Rare Outcomes: Lessons from West Nile Neuroinvasive Disease
Cahill M, Montgomery R. Analytical Approaches to Uncover Genetic Associations for Rare Outcomes: Lessons from West Nile Neuroinvasive Disease. Methods In Molecular Biology 2022, 2585: 193-203. PMID: 36331775, PMCID: PMC9867870, DOI: 10.1007/978-1-0716-2760-0_17.Peer-Reviewed Original ResearchConceptsWest Nile neuroinvasive diseaseNeuroinvasive diseaseViral infectionWest Nile viral infectionSevere neuroinvasive diseaseMore severe outcomesGenetic factorsRare outcomesLimited cohort sizeSevere West Nile neuroinvasive diseaseWest Nile infectionVector-borne viral infectionSevere outcomesImmune responseSevere diseaseHigh riskFatal diseaseVaccine developmentInfectionDiseaseInfected humansWest NileSerious diseaseOutcomesCohort size
2009
Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS)
Fischbach N, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). Journal Of Clinical Oncology 2009, 27: 8040-8040. DOI: 10.1200/jco.2009.27.15_suppl.8040.Peer-Reviewed Original ResearchNon-small cell lung cancerObservational cohort studyAdverse eventsClinical outcomesNSCLC ptsAdvanced non-small cell lung cancerARIES observational cohort studyMedian f/uAnti-VEGF monoclonal antibodyKey safety outcomeProtocol-specified treatmentSafety of bevacizumabCarboplatin/paclitaxelSerious adverse eventsPhase III trialsEffectiveness of bevacizumabCell lung cancerSubpopulation of patientsCohort sizePoor PSBrain metastasesChemotherapy regimenBaseline characteristicsCohort studyIII trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply